MCO
LAB icon

MAK Capital One’s Standard BioTools LAB Stock Holding History

MAK Capital One’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7M Buy
28,813,904
+2,641,278
+10% +$2.5M 3.32% 11
2026
Q1 		$24.1M Buy
26,172,626
+6,884,468
+36% +$8.33M 3.55% 10
2025
Q4 		$24.7M Buy
19,288,158
+3,356,352
+21% +$4.51M 2.72% 10
2025
Q3 		$20.7M Buy
15,931,806
+10,334,384
+185% +$13.5M 3.18% 8
2025
Q2 		$6.72M Buy
5,597,422
+2,822,701
+102% +$3.13M 0.96% 14
2025
Q1 		$3M Buy
+2,774,721
New +$3.9M 0.51% 10

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAK Capital One's LAB Position: Q2 2026 in Review

MAK Capital One increased its Standard BioTools (LAB) stake by 10% in Q2 2026, buying an estimated $2.5M and bringing the position to 28,813,904 shares worth $23.7M. The position accounts for 3.32% of the portfolio, ranked #11.

MAK Capital One first reported a position in LAB in Q1 2025 and has held it in 6 quarters since. The position peaked at $24.7M in Q4 2025. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • MAK Capital One held 28,813,904 shares of Standard BioTools worth $23.7M as of Q2 2026.
  • MAK Capital One bought 2,641,278 Standard BioTools shares in Q2 2026, an estimated $2.5M.
  • Standard BioTools made up 3.32% of MAK Capital One's portfolio in Q2 2026, its #11 holding.
  • MAK Capital One first reported a position in Standard BioTools in Q1 2025 and has held it in 6 quarters since.
  • MAK Capital One's Standard BioTools position peaked at $24.7M in Q4 2025.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on MAK Capital One's 13F filing for Q2 2026, filed 14 Aug 2026.